Literature DB >> 26092425

SRD5A2 gene expression inhibits cell migration and invasion in prostate cancer cell line via F-actin reorganization.

Suruchi Aggarwal1, Minu Singh1, Ashok Kumar2, Tapas Mukhopadhyay3.   

Abstract

Steroid 5-alpha reductase type 2 (SRD5A2) gene is important for normal development and functioning of prostate gland but it is reported to be silenced in metastatic prostate cancer. We showed that exogenous SRD5A2 expression in prostate cancer cell line reduced cell migration and invasion. Additionally, the stable transfectants showed enhanced adhesion to the matrix accompanied by changes in cytoskeletal organization, involving actin polymerization. siRNA knockdown of the endogenous SRD5A2 mRNA in LnCAP cells was effective, it reversed the phenotype, and thus induced cell motility. The MEK1 and pERK1/2 levels were found to be reduced in SRD5A2-expressing cells. Further, the reduced level of p38 protein was correlated with low expression of MMP-2 and MMP-7 genes. The results suggest that SRD5A2 controls cell migration by indirectly regulating ERK/MAPK pathway.

Entities:  

Keywords:  Actin cytoskeleton; Invasion; Migration; Prostate cancer; SRD5A2

Mesh：

Substances：

Year:  2015        PMID： 26092425     DOI： 10.1007/s11010-015-2478-z

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN： 0300-8177            Impact factor:   3.396


  31 in total

1.  Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination.

Authors:  S Nakamura; J A Roth; T Mukhopadhyay
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

2.  The Ras-ERK pathway modulates cytoskeleton organization, cell motility and lung metastasis signature genes in MDA-MB-231 LM2.

Authors:  C Choi; D M Helfman
Journal:  Oncogene       Date:  2013-09-02       Impact factor: 9.867

3.  Messenger ribonucleic acid levels of steroid 5 alpha-reductase 2 in human prostate predict the enzyme activity.

Authors:  T G Söderström; C Bjelfman; E Brekkan; B Ask; L Egevad; B J Norlén; A Rane
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

4.  Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer.

Authors:  Mark A Titus; Christopher W Gregory; O Harris Ford; Michael J Schell; Susan J Maygarden; James L Mohler
Journal:  Clin Cancer Res       Date:  2005-06-15       Impact factor: 12.531

5.  Differential gene expression of steroid 5 alpha-reductase 2 in core needle biopsies from malignant and benign prostatic tissue.

Authors:  C Bjelfman; T G Söderström; E Brekkan; B J Norlén; L Egevad; T Unge; S Andersson; A Rane
Journal:  J Clin Endocrinol Metab       Date:  1997-07       Impact factor: 5.958

6.  Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers.

Authors:  G J Gormley; E Stoner; R S Rittmaster; H Gregg; D L Thompson; K C Lasseter; P H Vlasses; E A Stein
Journal:  J Clin Endocrinol Metab       Date:  1990-04       Impact factor: 5.958

7.  The loss of 5alpha-reductase type I and type II mRNA expression in metastatic prostate cancer to bone and lymph node metastasis.

Authors:  Fouad K Habib; Margaret Ross; Colin W Bayne; Prasad Bollina; Ken Grigor; Karen Chapman
Journal:  Clin Cancer Res       Date:  2003-05       Impact factor: 12.531

8.  Molecular genetics of steroid 5 alpha-reductase 2 deficiency.

Authors:  A E Thigpen; D L Davis; A Milatovich; B B Mendonca; J Imperato-McGinley; J E Griffin; U Francke; J D Wilson; D W Russell
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

9.  Impairment of the ubiquitin-proteasome pathway by methyl N-(6-phenylsulfanyl-1H-benzimidazol-2-yl)carbamate leads to a potent cytotoxic effect in tumor cells: a novel antiproliferative agent with a potential therapeutic implication.

Authors:  Nilambra Dogra; Tapas Mukhopadhyay
Journal:  J Biol Chem       Date:  2012-06-28       Impact factor: 5.157

10.  A prospective randomized trial evaluating tissue effects of finasteride therapy in benign prostatic hyperplasia.

Authors:  M R Feneley; P N Span; J A Schalken; M Harper; K Griffiths; K Holmes; R S Kirby
Journal:  Prostate Cancer Prostatic Dis       Date:  1999-12       Impact factor: 5.554
View more
  7 in total

1.  Cytoskeleton disruption by the metabolic inhibitor 3-bromopyruvate: implications in cancer therapy.

Authors:  A Preto; M Casal; J Azevedo-Silva; D Tavares-Valente; A Almeida; O Queirós; F Baltazar; Y H Ko; P L Pedersen
Journal:  Med Oncol       Date:  2022-06-18       Impact factor: 3.064

2.  Dihydrotestosterone Induces Proliferation, Migration, and Invasion of Human Glioblastoma Cell Lines.

Authors:  Dulce Carolina Rodríguez-Lozano; Diana Elisa Velázquez-Vázquez; Aylin Del Moral-Morales; Ignacio Camacho-Arroyo
Journal:  Onco Targets Ther       Date:  2020-09-03       Impact factor: 4.147

3.  Retinoblastoma protein (Rb) links hypoxia to altered mechanical properties in cancer cells as measured by an optical tweezer.

Authors:  S Khakshour; M P Labrecque; H Esmaeilsabzali; F J S Lee; M E Cox; E J Park; T V Beischlag
Journal:  Sci Rep       Date:  2017-08-10       Impact factor: 4.379

4.  Analysis of STAT3 post-translational modifications (PTMs) in human prostate cancer with different Gleason Score.

Authors:  Rossana Cocchiola; Donatella Romaniello; Caterina Grillo; Fabio Altieri; Marcello Liberti; Fabio Massimo Magliocca; Silvia Chichiarelli; Ilaria Marrocco; Giuseppe Borgoni; Giacomo Perugia; Margherita Eufemi
Journal:  Oncotarget       Date:  2017-06-27

5.  Risk subtyping and prognostic assessment of prostate cancer based on consensus genes.

Authors:  Jialin Meng; Yu Guan; Bijun Wang; Lei Chen; Junyi Chen; Meng Zhang; Chaozhao Liang
Journal:  Commun Biol       Date:  2022-03-15

6.  A Novel Gene Signature-Based Model Predicts Biochemical Recurrence-Free Survival in Prostate Cancer Patients after Radical Prostatectomy.

Authors:  Run Shi; Xuanwen Bao; Joachim Weischenfeldt; Christian Schaefer; Paul Rogowski; Nina-Sophie Schmidt-Hegemann; Kristian Unger; Kirsten Lauber; Xuanbin Wang; Alexander Buchner; Christian Stief; Thorsten Schlomm; Claus Belka; Minglun Li
Journal:  Cancers (Basel)       Date:  2019-12-18       Impact factor: 6.639

7.  A four-gene signature associated with clinical features can better predict prognosis in prostate cancer.

Authors:  Penghui Yuan; Le Ling; Qing Fan; Xintao Gao; Taotao Sun; Jianping Miao; Xianglin Yuan; Jihong Liu; Bo Liu
Journal:  Cancer Med       Date:  2020-09-13       Impact factor: 4.452
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.